Evotec announced the launch of a second research collaboration Indivumed GmbH focused on the discovery of innovative new therapies for non-small cell lung cancer ("NSCLC"). This comes on the back of an initial collaboration in colorectal cancer ("CRC") which successfully identified three novel targets within three months by leveraging Indivumed's multi-omics cancer database, IndivuType, in combination with Evotec's PanHunter bioinformatics platform. The new agreement in lung cancer highlights Evotec's patient-centric approach to precision medicine which feeds patient data into the drug discovery process, facilitating increased success rates and lower costs. We reiterate both our OUTPERFORM recommendation and €28 target price.
24 Jan 2020
Building on progress in precision medicine
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Building on progress in precision medicine
Evotec SE (EVT:WBO) | 0 0 0.7% | Mkt Cap: 2,149m
- Published:
24 Jan 2020 -
Author:
Chris Redhead -
Pages:
5
Evotec announced the launch of a second research collaboration Indivumed GmbH focused on the discovery of innovative new therapies for non-small cell lung cancer ("NSCLC"). This comes on the back of an initial collaboration in colorectal cancer ("CRC") which successfully identified three novel targets within three months by leveraging Indivumed's multi-omics cancer database, IndivuType, in combination with Evotec's PanHunter bioinformatics platform. The new agreement in lung cancer highlights Evotec's patient-centric approach to precision medicine which feeds patient data into the drug discovery process, facilitating increased success rates and lower costs. We reiterate both our OUTPERFORM recommendation and €28 target price.